Business
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilizationFirst immune cell therapy (agenT-797) to show a survival benefit (70% vs. 10%) in patients with viral acute respiratory distress syndrome (ARDS) on respiratory bypassagenT-797 can be administered without lymphodepletion; with no reports of cytokine release syndrome or neurotoxicityNext-generation pipeline advances with two novel armored CAR-iNKTs, a FAP-CAR-iNKT and a BCMA-CAR-iNKT in IND-enabling studiesMiNK to host R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Invariant natural killer T (iNKT) cells are a powerful subset of T cells which act as master regulator of immune response, making them an ideal immunotherapy. MiNK has developed off-the-shelf, allogeneic iNKT (allo-iNKT) cell therapeutic candidates, agenT-797, in its native form or engineered for super targeting of a broad spectrum of diseases, including in solid cancers and viral diseases of the lung. “Our five presentations at SITC demonstrate the strength of progress at MiNK, including important new clinical data for agenT-797, advances across our differentiated next-generation programs, as well as our proprietary engineering technology,” said Dr. Jennifer Buell, President and CEO, of MiNK Therapeutics. “These collective data signify important advances in our understanding of iNKT cell science, elucidating novel mechanisms, and providing compelling clinical data of unmodified allo-iNKTs alone and combination with backbone immune checkpoint therapy in solid tumors. Our SITC 2022 data also represents the first immune cell therapy to show a survival benefit in patients with severe respiratory distress treated with respiratory bypass procedures.” Allogene...